#4-30E. Unmasking Joint Pain in Cancer Therapy: ICI-Associated Arthritis (ArthritisRheumatol, 2026)

How do you approach a cancer patient who develops severe joint pain without obvious swelling after starting immunotherapy? In this episode, we explore the complexities of immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA), a condition affecting approximately 6% of treated patients. While phenotypically resembling seronegative rheumatoid arthritis, the synovium in ICI-IA reveals a distinct microenvironment characterized by the clonal expansion of actively proliferating CD8+ T cells and IL-1β-high macrophages that communicate through specific chemokine axes. The most critical clinical takeaway is the imperative role of imaging; ultrasound and MRI frequently uncover significant subclinical synovitis and tenosynovitis even when physical examination shows no objective swelling, enabling prompt intervention. However, when critically appraising this paper, listeners should note that it is a narrative review rather than a primary research study, meaning it draws entirely from previously published literature and contains no new primary data. For clinicians, this paper is highly relevant as it not only guides the early detection and management of a debilitating adverse event to help patients remain on life-saving cancer therapies, but it also serves as a fascinating human model for understanding the preclinical evolution of classic inflammatory arthritis.

Citation: Kim ST, Bass AR. Immune checkpoint inhibitor-associated inflammatory arthritis. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.70128

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.